Alpha Tau Medical Ltd. DRTS

DRTS Company Overview

Alpha Tau Medical Ltd. is an Israel-based medical technology company focused on the development and commercialization of alpha-radiation cancer therapies. The company operates in the oncology and radiation therapy sectors and is best known for its proprietary Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) platform, which is designed to deliver localized alpha radiation directly into solid tumors. The company’s technology is intended to treat a range of cancers while minimizing damage to surrounding healthy tissue. Its primary revenue and value drivers currently stem from clinical development activities, regulatory advancement, research collaborations, and future commercialization potential tied to the Alpha DaRT platform.

The company was founded based on research originating from Tel Aviv University and technology developed by Professor Yona Keisari and Professor Itzhak Kelson. Alpha Tau Medical later evolved into a publicly traded company listed on Nasdaq under the ticker DRTS following a business combination transaction completed in 2022. The company has positioned itself within the emerging targeted radiotherapy market, emphasizing localized treatment approaches for solid tumors that may be difficult to treat through conventional surgery, chemotherapy, or external beam radiation.